Literature DB >> 15042292

[Radiofrequency ablation of liver metastases].

P L Pereira1, S Clasen, A Boss, D Schmidt, C Gouttefangeas, C Burkart, J Wiskirchen, G Tepe, C D Claussen.   

Abstract

The liver is the second only to lymph nodes as the most common site of metastatic disease irrespective of the primary tumor. Up to 50% of all patients with malignant diseases will develop liver metastases with a significant morbidity and mortality. Although the surgical resection leads to an improvement of the survival time, only approximately 20% of the patients are eligible for surgical intervention. Radiofrequency (RF) ablation represents one of the most important alternatives as well as complementary methods for the therapy of liver metastases. RF ablation can lead in a selected patient group to a palliation or to an increased life expectancy. RF ablation appears either safer (vs. cryotherapy) or easier (vs. laser) or more effective (percutaneous ethanol instillation [PEI], transarterial chemoembolisation [TACE]) in comparison with other minimal invasive procedures. RF ablation can be performed percutaneously, laparoscopically or intraoperatively and may be combined with chemotherapy as well as with surgical resection. Permanent technical improvements of RF systems, a better understanding of the underlying electrophysiological principles and an interdisciplinary approach will lead to a prognosis improvement in patients with liver metastases.

Entities:  

Mesh:

Year:  2004        PMID: 15042292     DOI: 10.1007/s00117-004-1033-9

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  33 in total

1.  Sonographically observed echogenic response during intraoperative radiofrequency ablation of cirrhotic livers: pathologic correlation.

Authors:  John R Leyendecker; Gerald D Dodd; Glenn A Halff; Victor A McCoy; Dacia H Napier; Linda G Hubbard; Kedar N Chintapalli; Shailendra Chopra; W Kenneth Washburn; Robert M Esterl; Francisco G Cigarroa; Ruth E Kohlmeier; Francis E Sharkey
Journal:  AJR Am J Roentgenol       Date:  2002-05       Impact factor: 3.959

Review 2.  The role of heat shock proteins and their receptors in the activation of the immune system.

Authors:  H Singh-Jasuja; N Hilf; D Arnold-Schild; H Schild
Journal:  Biol Chem       Date:  2001-04       Impact factor: 3.915

3.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

Review 4.  Hepatic metastases: basic principles and implications for radiologists.

Authors:  M E Baker; R Pelley
Journal:  Radiology       Date:  1995-11       Impact factor: 11.105

Review 5.  [Indications and outcome of liver metastases resection].

Authors:  T Lehnert; M Golling
Journal:  Radiologe       Date:  2001-01       Impact factor: 0.635

Review 6.  Therapeutic alternatives in metastatic neuroendocrine tumors.

Authors:  C A Miller; E C Ellison
Journal:  Surg Oncol Clin N Am       Date:  1998-10       Impact factor: 3.495

7.  Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients.

Authors:  T Livraghi; S N Goldberg; L Solbiati; F Meloni; T Ierace; G S Gazelle
Journal:  Radiology       Date:  2001-07       Impact factor: 11.105

8.  Percutaneous US-guided radio-frequency tissue ablation of liver metastases: treatment and follow-up in 16 patients.

Authors:  L Solbiati; T Ierace; S N Goldberg; S Sironi; T Livraghi; R Fiocca; G Servadio; G Rizzatto; P R Mueller; A Del Maschio; G S Gazelle
Journal:  Radiology       Date:  1997-01       Impact factor: 11.105

9.  Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications.

Authors:  T F Wood; D M Rose; M Chung; D P Allegra; L J Foshag; A J Bilchik
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

10.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  4 in total

1.  [Radiofrequency ablation as a palliative therapy option in ENT tumors: in vivo and in vitro testing].

Authors:  S Bucher; J Hornung; V Bonkowsky; H Iro; J Zenk
Journal:  HNO       Date:  2010-04       Impact factor: 1.284

2.  [Liver tumor ablation].

Authors:  Th Helmberger; R-Th Hoffmann; T Jakobs; Th Leibecke; A Lubienski; M Reiser
Journal:  Radiologe       Date:  2005-01       Impact factor: 0.635

3.  Techniques of interventional tumor therapy.

Authors:  Andreas H Mahnken; Philipp Bruners; Rolf W Günther
Journal:  Dtsch Arztebl Int       Date:  2008-09-19       Impact factor: 5.594

Review 4.  [Combined therapies including interventional radiology].

Authors:  S Clasen; P L Pereira
Journal:  Radiologe       Date:  2007-12       Impact factor: 0.803

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.